Figure 3 | Scientific Reports

Figure 3

From: Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

Figure 3

Study design. (A) Whole Cohort. (B) Cohort 1, Cohort 2 and Cohort 3 stratified by recurrence risk. HR hormone receptor, HER2 human epidermal growth factor receptor 2. HER2-zero group: Patients with immunohistochemistry (IHC) 0 score. HER2-low group: Patients with IHC1+ or IHC2+/fluorescence in situ hybridization (FISH)—scores. Cohort 1: Patients with ≥ 4 positive axillary lymph nodes (ALNs), or 1–3 positive ALNs, and either histological grade (HG) 3 or tumor size ≥ 5 cm. Cohort 2: Patients with 1–3 positive ALNs, HG < 3, tumor size < 5 cm, and high Ki-67 index (≥ 20%). Cohort 3: Patients with 1-3 positive ALNs, HG < 3, tumor size < 5 cm, and low Ki-67 index (< 20%). 

Back to article page